Overview
PMN market data
Price History
PMN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.07 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.26 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -12,900.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.27 – $27.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $132.6M · P/B 1.88 · P/S 13,263.22.
Company News
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100Benzinga · Aug 14, 2026, 1:29 PM
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · Aug 13, 2026, 9:24 PM
8-K filing — ProMIS Neurosciences Inc. (PMN)SEC EDGAR · Aug 13, 2026, 8:07 PM
ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) EstimateBenzinga · Aug 13, 2026, 8:01 PM
Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $69Benzinga · Jul 29, 2026, 2:14 PM
ProMIS Neurosciences shares are trading higher. The company announced blinded six-month interim safety and biomarker results for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s disease trial.Benzinga · Jul 28, 2026, 6:13 PM
12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga · Jul 28, 2026, 5:06 PM
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's StudyBenzinga · Jul 28, 2026, 4:30 PM
Chardan Capital Maintains Buy on ProMIS Neurosciences, Raises Price Target to $33Benzinga · Jul 28, 2026, 3:24 PM
Market-Moving News for July 28thBenzinga · Jul 28, 2026, 11:21 AM